VivoSeq
Other

Weight Management

3

Pipeline Programs↗

6

Active Trials↗

10

Companies Involved↗

Weight Management is an early-stage landscape with 3 programs across 10 companies. The most active players are Gilead, Fujian Shengdi Pharmaceutical Co., Ltd., Dexcel Pharma Technologies Ltd.. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

15/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Gilead logo

Gilead

1 program

Phase 1F

Fujian Shengdi Pharmaceutical Co., Ltd.

1 program

Phase 1D

Dexcel Pharma Technologies Ltd.

1 program

Phase 1AstraZeneca logo

AstraZeneca

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3A

Ascletis Pharma (China) Co., Limited

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 12

GS-4571

Gilead

Omeprazole

Dexcel Pharma Technologies Ltd.

Phase 2
No programs
Phase 31

Elecoglipron

AstraZeneca

Approved
No programs

Analysis

Trial Status

20

clinical trials

Completed13 · 65%
Not yet recruiting3 · 15%
Recruiting2 · 10%
Active, not recruiting1 · 5%
Unknown status1 · 5%

Clinical Trials

Trial Activity

20 trials

A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus (Embold)
Recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT07667803·4,500 enrolled
A Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Oral Doses of GS-4571 in Healthy Participants, Multiple Ascending Oral Doses of GS-4571 in Nondiabetic Obese Participants and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM), and to Evaluate the Effect of Food and an Acid-Reducing Agent on Pharmacokinetics of GS-4571
Recruiting·Gilead logoGilead·Phase 1·NCT06562907·134 enrolled
VK2735 for Weight Management Phase 3
Active, not recruiting·VViking Therapeutics, Inc.·Phase 3·NCT07104500·4,500 enrolled
Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCT
Not yet recruiting·—·N/A·NCT07326839·120 enrolled
A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
Not yet recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logoChia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT06738979·408 enrolled
A Phase I Clinical Study to Evaluate the Effect of Different Dosing Conditions on the Pharmacokinetics of HRS9531 Tablets in Healthy Participants
Not yet recruiting·FFujian Shengdi Pharmaceutical Co., Ltd.·Phase 1·NCT06506175·100 enrolled
Effectiveness of Brief Counseling for Weight Management
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 4·NCT00212199·246 enrolled
Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.
Completed·Novo Nordisk logoNovo Nordisk·N/A·NCT06283641·300 enrolled
Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management
Completed·MMayo Clinic·Phase 3·NCT02129608·44 enrolled
Biomarker Feedback on Health and Wellbeing and Exercise Adherence Following a 6 Month Weight Management Course
Completed·UUniversity of Hertfordshire·N/A·NCT03809871·43 enrolled
VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
Completed·VViking Therapeutics, Inc.·Phase 2·NCT06828055·280 enrolled
Adolescent Weight Management Study
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT00212173·120 enrolled
Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic
Completed·SScripps Whittier Diabetes Institute·N/A·NCT03552107·157 enrolled
In-market Utilisation of Liraglutide Used for Weight Management in Europe
Completed·Novo Nordisk logoNovo Nordisk·N/A·NCT02967757·316 enrolled
Endoscopic Gastric Reduction for Weight Management
Completed·MMayo Clinic·Phase 1·NCT01682733·10 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)